Register a trial

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.


With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04526951




Registration number
NCT04526951
Ethics application status
Date submitted
20/08/2020
Date registered
26/08/2020

Titles & IDs
Public title
TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS)
Scientific title
TENecteplase in Central Retinal Artery Occlusion Study (TenCRAOS): a Randomized Placebo-controlled Trial of Early Systemic Tenecteplase Treatment in Patients with Central Retinal Artery Occlusion.
Secondary ID [1] 0 0
2018-002546-36
Secondary ID [2] 0 0
Oslo UH
Universal Trial Number (UTN)
Trial acronym
TenCRAOS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Central Retinal Artery Occlusion 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Intravenous injection of Tenecteplase and one dose of placebo tablet
Treatment: Drugs - One tablet of Acetylsalicylic Acid and one dose of IV placebo

Active comparator: Tenecteplase - The total dose of tenecteplase is 0.25 mg/kg body weight, maximum 25 mg. The total dose will be given as an intravenous bolus

Active comparator: acetylsalicylic acid - one tablet of aspirin 300 mg Other Name: Aspirin


Treatment: Drugs: Intravenous injection of Tenecteplase and one dose of placebo tablet
Drug: Tenecteplase Tenecteplase administered as an intravenous injection (0.25 mg/kg body weigh; maximum 25 mg)

Treatment: Drugs: One tablet of Acetylsalicylic Acid and one dose of IV placebo
300 mg Acetylsalisylic acid
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of patients with = 0.7 logMAR visual acuity in the affected eye at 30 (±5) days after treatment, representing an improvement in visual acuity of at least 0.3 logMAR (intention-to-treat (ITT) analysis).
Assessment method [1] 0 0
logMAR
Timepoint [1] 0 0
30 (±5) days
Secondary outcome [1] 0 0
Proportion of patients with = 0.5 logMAR visual acuity in the affected eye at 30 (±5) and 90 (±15) days.
Assessment method [1] 0 0
logMAR
Timepoint [1] 0 0
30 (±5) and 90 (±15) days
Secondary outcome [2] 0 0
Mean improvement in logMAR visual acuity in the affected eye from baseline to 30 (±5) and 90 (±15) days.
Assessment method [2] 0 0
logMAR
Timepoint [2] 0 0
30 (±5) and 90 (±15) days
Secondary outcome [3] 0 0
Proportion of patients with visual recovery (logMAR = 0.7) and (logMAR = 0.5) in the affected eye 30 (±5) and 90 (±15) days in patients who were treated with tenecteplase within 3 hours of onset
Assessment method [3] 0 0
logMAR
Timepoint [3] 0 0
30 (±5) and 90 (±15) days
Secondary outcome [4] 0 0
Number of test points seen (of 100) on monocular Esterman perimetry at 30 (±5) and 90 (±15) days
Assessment method [4] 0 0
Number of test points
Timepoint [4] 0 0
30 (±5) and 90 (±15) days
Secondary outcome [5] 0 0
Acute ischemic lesions on follow-up on diffusion-weighted (DWI) MRI or on brain CT at baseline and 24hrs.
Assessment method [5] 0 0
DWI lesions
Timepoint [5] 0 0
24 hours
Secondary outcome [6] 0 0
National Institutes of Health Stroke Scale score (NIHSS) at 24hrs and discharge.
Assessment method [6] 0 0
NIHSS score
Timepoint [6] 0 0
24 hours
Secondary outcome [7] 0 0
Modified Rankin Scale score (mRS) at discharge, 30 (±5) and 90 days (±15) days.
Assessment method [7] 0 0
mRS score
Timepoint [7] 0 0
Discharge, 30 (±5) and 90 days (±15) days.
Secondary outcome [8] 0 0
Mean score on National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) at 30 (±5) and 90 (±15) days
Assessment method [8] 0 0
Visual function related quality of life at 30 and 90 days. Measures the dimensions of self-reported vision-targeted health status that are most important for persons who have chronic eye diseases. 100 = best possible, 0 = worst possible
Timepoint [8] 0 0
30 (±5) and 90 (±15) days
Secondary outcome [9] 0 0
Mean score on EQ-5D at 30 (±5) and 90 (±15) days
Assessment method [9] 0 0
Quality of life reported at 30 and 90 days. Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Timepoint [9] 0 0
30 (±5) and 90 (±15) days
Secondary outcome [10] 0 0
Presence of ocular neovascularisation at 30 (±5) and 90 (±15) days
Assessment method [10] 0 0
presence
Timepoint [10] 0 0
30 (±5) and 90 (±15) days

Eligibility
Key inclusion criteria
1. Non-arteritic central retinal artery occlusion with = 1.0 logMAR visual acuitiy and symptoms lasting less than 4.5 hours.
2. Ability to administer the Investigator Medicinal Product (IMP) within 4.5 hours of symptom onset.
3. Age =18 years.
4. Informed written consent of the patient.
5. A woman of childbearing potential (WOCBP) must confirm that in her opinion, she cannot be pregnant, OR if there is a possibility that she is pregnant, a negative pregnancy test must be confirmed before any IMP is given.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. No other active intervention targeting CRAO.
2. Branch retinal artery occlusion, cilioretinal artery supplying the macula, combined arterial-venous occlusion, proliferative diabetic retinopathy, elevated intraocular pressure (> 30 mmHg) or clinical suspicion of ophthalmic artery occlusion occlusion (e.g. choroidal nonperfusion, absence of cherry red spot, no light perception).
3. Systemic diseases; severe general diseases, systemic arterial hypertension (blood pressure >185/110 mmHg), despite medical therapy, or clinical suspicion of acute systemic inflammation.
4. Presence of intracranial haemorrhage on brain MRI/CT.
5. Medical history: heart attack within the last 6 weeks, intracerebral bleeding or neurosurgical operation within the last 4 weeks, therapy with anticoagulation, allergic reaction to contrast agent, hemorrhagic diathesis, aneurysms, inflammatory vascular diseases (eg, giant cell arteritis, granulomatosis with polyangitis), endocarditis, or gastric ulcer.
6. No willingness and ability of the patient to participate in all follow-up examinations.
7. Pregnancy (if suspicion of pregnancy s-hCG or u-hCG must be negative).
8. Allergy or intolerance to any ingredients of IMP or placebo or gentamicin.
9. Other conditions / circumstances likely to lead to poor treatment adherence (eg, history of poor compliance, alcohol or drug dependency, no fixed abode).
10. Significant bleeding disorder either at present or within the past 6 months.
11. Effective oral anticoagulant treatment, eg, warfarin sodium (INR >1.3).
12. Effective anticoagulant treatment with heparin or low molecular weight heparin the last 48 hours.
13. Any history of central nervous system damage (ie, neoplasm, aneurysm, intracranial or spinal surgery).
14. Known hemorrhagic diathesis.
15. Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with acute myocardial infarction).
16. Recent non-compressible vessel puncture within 2 weeks.
17. Recent trauma to the head or cranium.
18. Prolonged cardiopulmonary resuscitation (>2 minutes) within the past 2 weeks.
19. Acute pericarditis and/or subacute bacterial endocarditis.
20. Acute pancreatitis.
21. Severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis.
22. Active peptic ulceration.
23. Arterial aneurysm and known arterial/venous malformation.
24. Neoplasm with increased bleeding risk.
25. Any known history of hemorrhagic stroke or stroke of unknown origin.
26. Known history of ischemic stroke or transient ischemic attack in the preceding 3 months.
27. Dementia.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/10/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/03/2025
Actual
Sample size
Target
78
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
St Vincent's Hospital Melbourne - Melbourne
Recruitment postcode(s) [1] 0 0
- Melbourne
Recruitment outside Australia
Country [1] 0 0
Belgium
State/province [1] 0 0
Anderlecht
Country [2] 0 0
Belgium
State/province [2] 0 0
Antwerp
Country [3] 0 0
Belgium
State/province [3] 0 0
Brussel
Country [4] 0 0
Belgium
State/province [4] 0 0
Leuven
Country [5] 0 0
Denmark
State/province [5] 0 0
Aarhus
Country [6] 0 0
Denmark
State/province [6] 0 0
Copenhagen
Country [7] 0 0
Finland
State/province [7] 0 0
Helsinki
Country [8] 0 0
Finland
State/province [8] 0 0
Turku
Country [9] 0 0
Ireland
State/province [9] 0 0
Dublin
Country [10] 0 0
Lithuania
State/province [10] 0 0
Kaunas
Country [11] 0 0
Lithuania
State/province [11] 0 0
Vilnius
Country [12] 0 0
Norway
State/province [12] 0 0
Arendal
Country [13] 0 0
Norway
State/province [13] 0 0
Bergen
Country [14] 0 0
Norway
State/province [14] 0 0
Drammen
Country [15] 0 0
Norway
State/province [15] 0 0
Grålum
Country [16] 0 0
Norway
State/province [16] 0 0
Lillehammer
Country [17] 0 0
Norway
State/province [17] 0 0
Molde
Country [18] 0 0
Norway
State/province [18] 0 0
Namsos
Country [19] 0 0
Norway
State/province [19] 0 0
Oslo
Country [20] 0 0
Norway
State/province [20] 0 0
Skien
Country [21] 0 0
Norway
State/province [21] 0 0
Stavanger
Country [22] 0 0
Norway
State/province [22] 0 0
Tromsø
Country [23] 0 0
Norway
State/province [23] 0 0
Trondheim
Country [24] 0 0
Norway
State/province [24] 0 0
Tønsberg
Country [25] 0 0
Sweden
State/province [25] 0 0
Stockholm
Country [26] 0 0
Sweden
State/province [26] 0 0
Sundsvall

Funding & Sponsors
Primary sponsor type
Other
Name
Oslo University Hospital
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Anne Hege Aamodt
Address 0 0
Country 0 0
Phone 0 0
+47 23074976
Email 0 0
a.h.aamodt@medisin.uio.no
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04526951